Compare Merck & Co., Inc. (MRK) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Toyota Motor Corp — how do they compare? Merck & Co., Inc. trades at $131.9 (market cap $321.77B), while Toyota Motor Corp trades at $188.71 (market cap $221.79B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Toyota Motor Corp pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| MRK | TM | |
|---|---|---|
Market Cap | $321.77B | $221.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $131.84 | $248.29 |
52-Week Low | $77.60 | $166.50 |
Enterprise Value | $368.53B | $414.06B |
Dividend Yield | 2.61% | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Toyota Motor (TM) trades at $188.97, up 0.1% on the day, with a bullish technical signal from moving averages. The stock presents attractive valuation metrics, including a P/E of 8.53 and P/B of 0.95, trading below book value. Recent quarterly earnings have consistently beaten expectations, though Q1 2026 results missed estimates due to higher costs, as reported by Zacks Investment Research on August 6, 2026. Cash flow trends show volatility, with a net outflow in 2025 but a projected recovery in 2026.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside, but risks include recall costs, China sales weakness, and margin pressure. Institutional sentiment is cautiously optimistic, with no sell ratings among covered analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
